li001

Results from the Phase 2 ROSETTA Lung-02 study p suggest that pumitamig, an experimental bispecific antibody targeting PD-L1 and VEGF-A, may be a promising first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) when combined with chemotherapy. Among 40 patients enrolled in the study, the treatment achieved a 100% confirmed disease control rate. […]

A new subgroup analysis from the Phase 3 PSMAddition trial  shows that adding the radioligand therapy Pluvicto to standard hormone-based treatment significantly improves outcomes for patients with metastatic hormone-sensitive prostate cancer. Researchers found that the treatment reduced the risk of disease progression on imaging by a similar amount across all patient groups, including those with

A new experimental drug, emiltatug ledadotin (Emi-Le), has shown encouraging results for patients with aggressive adenoid cystic carcinoma (ACC), a rare cancer that currently has no approved systemic treatments. Findings revealed that the B7-H4–targeted antibody-drug conjugate produced strong tumor responses in patients with advanced disease. Among 32 patients with particularly aggressive ACC, nearly 47% experienced

A combination of cadonilimab, a dual PD-1/CTLA-4 immunotherapy, and axitinib showed promising results as a first-line treatment for advanced non–clear cell renal cell carcinoma (nccRCC). In a phase 1b/2 trial involving 37 patients, the treatment achieved an objective response rate of 51.6%, while 96.8% of patients experienced disease control. The median progression-free survival was 14.2

A real-world study evaluated tarlatamab (Imdelltra) in 23 patients with extensive-stage small cell lung cancer (ES-SCLC), a group with higher disease burden than typical clinical trials. Many patients were older (median age 72), 61% had brain metastases, and 43% had received two or more prior treatments. Among 18 evaluable patients, the objective response rate was